The U.S. Health Resources and Services Administration yesterday posted notices of refunds for 340B overcharges from drug manufacturers Lilly, Novo Nordisk, and Neurocrine and a notice from Amneal about product NDC changes.
Lilly
Lilly’s May 30 notice covers purchases
…
Health care providers in Guam eligible to participate in the 340B program may do so immediately, rather than having to wait for the next normal quarterly registration period July 1-15, the U.S. Health Resources and Services Administration said yesterday.
Secretary
…
Drug manufacturer Merck is paying refunds for overcharges on 340B drugs purchased during the first two quarters of 2020.
Merck recently asked the U.S. Health Resources and Services Administration to post notices about its 340B ceiling price recalculations on the
…
The U.S. Centers for Medicare & Medicaid Services has sent its proposed remedy for almost five years of illegal Medicare Part B drug payments cuts for 340B hospitals to the White House for clearance to be published in the Federal
…
The U.S. Centers for Medicare & Medicaid Services wants to make Medicaid managed care organizations use Medicaid-specific codes and group numbers on beneficiary insurance cards to help states, MCOs, and 340B covered entities avoid invoicing manufacturers for prohibited duplicate 340B
…
Federal 340B program officials confirmed last week that providers granted immediate 340B enrollment under a COVID-19 public health emergency flexibility are not losing their 340B eligibility and will not need to re-enroll now that the PHE is over.
The U.S.
…
Drug manufacturers Amgen and GlaxoSmithKline have notified 340B covered entities about refunds for overcharges, Amgen for sales in 2020 and GSK for sales in 2021.
The U.S. Health Resources and Services Administration posted both companies’ notices on its website yesterday.
…
Correspondence in April and May 2020 between the 340B prime vendor and a law firm sheds more light on the start of a policy that the federal government ended abruptly last week that let hospitals start using 340B drugs at
…
The U.S. Health Resources and Services Administration midday yesterday and the 340B prime vendor Apexus this morning, in connection with the end of the COVID-19 public health emergency late last night, withdrew mostly identical 340B program FAQs about use of
…
Drug manufacturer Janssen Pharmaceuticals said last week it would pay refunds for overcharges on 340B drugs purchased in the second quarter of 2020, including top-selling psoriasis drug Stelara.
Janssen, part of Johnson & Johnson, said it owes or may owe
…*Sign up for news summaries and alerts from 340B Report